AXL and ovarian carcinoma: In parallel, combined treatment with VS-6766/CH5126766 and AXL inhibitor (bemcentinib) has provided a stronger blockage of tumor growth in KRAS-mutant ovarian cancer cells with overexpressed AXL [113].